LEA
REGN icon

Legacy Edge Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Legacy Edge Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-211
Closed -$222K – 186
2024
Q3 		$222K Sell
211
-1
-0.5% -$1.11K 0.04% 173
2024
Q2 		$223K Buy
+212
New +$206K 0.04% 165

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Legacy Edge Advisors's REGN Position: Q4 2024 in Review

Legacy Edge Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 211 shares — an estimated $222K sold.

Legacy Edge Advisors first reported a position in REGN in Q2 2024 and held it in 2 quarters. The position peaked at $223K in Q2 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Legacy Edge Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Legacy Edge Advisors sold 211 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $222K.
  • Legacy Edge Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Legacy Edge Advisors's Regeneron Pharmaceuticals position peaked at $223K in Q2 2024.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Legacy Edge Advisors's 13F filing for Q4 2024, filed 17 Aug 2026.